With 0.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.8 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $45.95 whereas the lowest price it dropped to was $44.58. The 52-week range on PTCT shows that it touched its highest point at $54.16 and its lowest point at $23.58 during that stretch. It currently has a 1-year price target of $58.71. Beta for the stock currently stands at 0.62.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PTCT was down-trending over the past week, with a drop of -1.02%, but this was up by 1.46% over a month. Three-month performance surged to 23.37% while six-month performance rose 46.84%. The stock gained 60.15% in the past year, while it has gained 66.07% so far this year. A look at the trailing 12-month EPS for PTCT yields -5.94 with Next year EPS estimates of -0.49. For the next quarter, that number is -0.76. This implies an EPS growth rate of 44.36% for this year and 89.43% for next year. EPS is expected to decline by -9.51% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -24.94%.
Float and Shares Shorts:
At present, 76.95 million PTCT shares are outstanding with a float of 74.46 million shares on hand for trading. On 2024-12-13, short shares totaled 4.59 million, which was 594.9999799999999 higher than short shares on 1731628800. In addition to Dr. Matthew B. Klein F.A.C.S., M.D., M.S. as the firm’s CEO & Director, Dr. Stuart W. Peltz Ph.D. serves as its Co-Founder, Senior Consultant & Member of Scientific Advisory Board.
Institutional Ownership:
Through their ownership of 1.04126 of PTCT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PTCT reported revenue of $196786000.0 and operating income of -$51966000.0. The EBITDA in the recently reported quarter was -$47352000.0 and diluted EPS was -$1.39.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PTCT since 7 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 2 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PTCT analysts setting a high price target of 80.0 and a low target of 32.0, the average target price over the next 12 months is 58.71429. Based on these targets, PTCT could surge 74.79% to reach the target high and fall by -30.09% to reach the target low. Reaching the average price target will result in a growth of 28.28% from current levels.
Analysts have provided yearly estimates in a range of -$3.70655 being high and -$5.20818 being low. For PTCT, this leads to a yearly average estimate of -$4.65695. Based on analyst estimates, the high estimate for the next quarter is -$1.3 and the low estimate is -$1.3. The average estimate for the next quarter is thus -$1.3.
